Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Thousands of premature babies in the UK can now be protected against a common winter virus which can cause a dangerous lung ...

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

A single, long-lasting jab that offers a “protective bubble” to premature babies from a common virus is set to be rolled out ...

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...